RxDoctor Payments DataLook up a doctor →

Timothy Prestley, MD

Neurology · Tuscaloosa, ALNPI 1548421803

Payments from drug & device makers

$256,475in general payments, 2019–2025

Across 1,900 payments — averaging $134.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$175K
  • Brainsway USA Inc$47K
  • Pfizer$10K
  • UCB, Inc.$2K
  • Amgen$1K
  • Novartis$1K
  • plus $20K from 54 others

What the payments were for

  • Consulting fees$1,5251%
  • Speaking & faculty fees$174,73783%
  • Travel & lodging$2,0231%
  • Food & beverage$31,19715%
  • Education$4130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)494$174,568
Brainsway USA Inc1$46,580
Pfizer102$10,124
UCB, Inc.115$2,380
Amgen(2 entities)66$1,247
Novartis73$1,149
CSL Behring33$1,146
AstraZeneca(2 entities)49$1,085
Johnson & Johnson(2 entities)46$1,035
Teva Pharmaceuticals USA, Inc.69$1,010
SK Life Science, Inc.45$1,001
Argenx US, Inc.40$978
Lundbeck LLC41$887
Merz Pharmaceuticals, LLC34$873
Biogen56$843
Otsuka America Pharmaceutical, Inc.48$825
Lilly USA, LLC53$761
Takeda Pharmaceuticals U.S.A., Inc.37$750
Acadia Pharmaceuticals Inc53$747
Eisai Inc.33$698
Neurocrine Biosciences, Inc.27$578
Catalyst Pharmaceuticals, Inc.24$558
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)29$534
Axsome Therapeutics, Inc.26$509
Neurelis, Inc.29$464
Sunovion Pharmaceuticals Inc.28$432
Biohaven Pharmaceutical Holding Company Ltd.13$306
Impel Pharmaceuticals Inc.14$270
Jazz Pharmaceuticals Inc.13$262
Grifols USA, LLC14$250
Supernus Pharmaceuticals, Inc.13$245
Avanir Pharmaceuticals, Inc.15$239
Sumitomo Pharma America, Inc.11$223
Upsher-smith Laboratories LLC11$220
Vanda Pharmaceuticals Inc.9$210
Genentech USA, Inc.10$210
Biohaven Pharmaceuticals, Inc.10$199
Amneal Pharmaceuticals LLC13$193
Acorda Therapeutics, Inc11$191
Greenwich Biosciences, Inc.9$167
Akcea Therapeutics, Inc.9$152
Scilex Pharmaceuticals Inc.7$150
Kyowa Kirin, Inc.5$103
Tanabe Pharma America, Inc.6$103
Tris Pharma Inc5$96
Harmony Biosciences LLC4$94
Octapharma USA, Inc.3$74
EMD Serono, Inc.4$72
Sanofi4$70
Otsuka Pharmaceutical Development & Commercialization, Inc.3$64
Adamas Pharmaceuticals, Inc.3$58
MDD US Operations, LLC3$55
Almatica Pharma LLC3$53
Aquestive Therapeutics, Inc.3$49
Mallinckrodt Hospital Products Inc.2$47
Assertio Therapeutics, Inc.3$41
Zyla Life Sciences, Inc.2$33
Ipsen Biopharmaceuticals, Inc2$29
Arbor Pharmaceuticals, Inc.2$28
Averitas Pharma Inc.1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$256,475 in reported general payments places this provider in the 90th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$445,577
Medicare patients
462
Services billed
54,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab13$909,196
SolirisEculizumab24$655,442
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5013$349,974
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5022$141,838
BotoxOnabotulinumtoxina86$130,141
Kesimpta PenOfatumumab11$96,091
XcopriCenobamate59$71,243
QuliptaAtogepant46$58,227
UbrelvyUbrogepant35$54,890
EpidiolexCannabidiol (Cbd)20$53,279
XeominIncobotulinumtoxina32$41,740
BriviactBrivaracetam21$28,561
Emgality PenGalcanezumab-Gnlm13$19,795
VimpatLacosamide14$15,571
Aimovig AutoinjectorErenumab-Aooe14$10,164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$978$909,19613 claims
AstraZenecaSoliris$1,085$655,44224 claims
AbbVieBotox, Qulipta, Ubrelvy$174,568$243,259167 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix$750$147,06033 claims
SK Life Science, Inc.Xcopri$1,001$71,24359 claims
UCB, Inc.Briviact, Vimpat$2,380$44,13235 claims
Almatica Pharma LLCGralise$53$6,52214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 neurology providers in Alabama.

Other neurology in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →